Dapagliflozin rescues vasculogenic capacity of endothelial progenitor cells in diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047733

Enrollment

Unknown

Registered

2021-06-25

Start date

2020-02-01

Completion date

Unknown

Last updated

2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

Case series:Dapagliflozin

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male; 2. Aged 18 to 70 years; 3. Diagnosed with type 2 diabetes for less than 3 months according to American Diabetes Association diagnostic glucose criteria.

Exclusion criteria

Exclusion criteria: T1DM, malignancy, cardiovascular events, liver disease, chronic renal failure, autoimmune diseases, or active inflammatory disease and those with other comorbidities, or other situations judged by researchers as unsuitable for participation in the study.

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose;	—

Secondary

Measure	Time frame
HbA1c;Retinal capillary density;Vasculogenic capacity of endothelial progenitor cells;	—

Countries

China

Contacts

Public ContactWenhao Xia

Department of Hypertension and Vascular Disease, the First Affiliated Hospital of Sun Yat-Sen University

xiawhao@mail.sysu.edu.cn+86 15818193120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026